Homepage
Medication Guide
Dosage and Administration of Qutenza (Capsaicin Patch)
Qutenza (Capsaicin Patch) is an FDA-approved topical medication for the treatment of postherpetic neuralgia (PHN) and neuropathic pain associated with diabetic peripheral neuropathy (DPN). Its unique ...
511
Monday, November 17th, 2025, 09:33
What Are the Indications for Qutenza (Capsaicin Patch)?
Qutenza (Capsaicin Patch) is a therapeutic medication approved by the U.S. Food and Drug Administration (FDA), providing an innovative treatment option for patients with specific types of neuropathic ...
508
Monday, November 17th, 2025, 09:28
Purchase Channels for Qutenza (Capsaicin Patch)
Qutenza (Capsaicin Patch) is a topical patch containing 8% capsaicin, classified as a TRPV1 channel agonist. In July 2020, this medication was approved by the U.S. FDA for the treatment of foot neural...
511
Monday, November 17th, 2025, 09:24
What Are the Side Effects of Epalrestat?
Epalrestat is a selective aldose reductase inhibitor. Since its approval in Japan in 1992, it has been mainly used for the treatment of diabetic peripheral neuropathy. Similar to other medications, Ep...
529
Monday, November 17th, 2025, 09:22
What are the Precautions for Taking Epalrestat?
Epalrestat is an aldose reductase inhibitor. Since its approval in Japan in 1992, it has been widely used as an adjuvant treatment for diabetic peripheral neuropathy.What are the Precautions for Takin...
513
Monday, November 17th, 2025, 09:18
Dosage and Administration of Epalrestat: Recommended Dosage
Epalrestat is a selective aldose reductase inhibitor. Since its approval in Japan in 1992, it has become an important therapeutic agent for diabetic peripheral neuropathy.Dosage and Administration of ...
516
Friday, November 14th, 2025, 14:02
What Are the Indications of Epalrestat?
Epalrestat is an aldose reductase inhibitor that holds an important position in the treatment of diabetic complications. Since its first approval in Japan in 1992, it has become one of the key medicat...
509
Friday, November 14th, 2025, 13:28
Procurement Channels for Epalrestat
Epalrestat is an aldose reductase inhibitor that was first approved in Japan in 1992. It is mainly used for the treatment of diabetic peripheral neuropathy. Its mechanism of action involves inhibiting...
512
Friday, November 14th, 2025, 13:24
What Are the Precautions for Taking Dimemorfan Phosphate Tablets (Astomin)?
Dimemorfan Phosphate Tablets (Astomin) are a type of non-narcotic central antitussive. Since its first approval in Japan in 1975, it has been widely used to relieve cough symptoms in adults due to its...
506
Friday, November 14th, 2025, 13:19
What Are the Indications of Dimemorfan Phosphate Tablets (Astomin)?
Dimemorfan Phosphate Tablets (Astomin) are non-narcotic central antitussives. Owing to their low side effects and low addictiveness, they exhibit unique value in clinical practice.What Are the Indicat...
515
Friday, November 14th, 2025, 13:12
63 / 214
2139 in total
Departments
Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved